The Role of Non-Coding RNAs in the Neuroprotective Effects of Glutathione

Chisato Kinoshita * and Koji Aoyama *

Department of Pharmacology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan
* Correspondence: ciitaka@med.teikyo-u.ac.jp (C.K.); kaoyama@med.teikyo-u.ac.jp (K.A.); Tel.: +81-3-3964-3794 (C.K.); +81-3-3964-1211 (K.A.)

Abstract: The establishment of antioxidative defense systems might have been mandatory for most living beings with aerobic metabolisms, because oxygen consumption produces adverse byproducts known as reactive oxygen species (ROS). The brain is especially vulnerable to the effect of ROS, since the brain has large amounts of unsaturated fatty acids, which are a target of lipid oxidation, as well as comparably high-energy consumption compared to other organs that results in ROS release from mitochondria. Thus, dysregulation of the synthesis and/or metabolism of antioxidants—particularly glutathione (GSH), which is one of the most important antioxidants in the human body—caused oxidative stress states that resulted in critical diseases, including neurodegenerative diseases in the brain. GSH plays crucial roles not only as an antioxidant but also as an enzyme cofactor, cysteine storage form, the major redox buffer, and a neuromodulator in the central nervous system. The levels of GSH are precisely regulated by uptake systems for GSH precursors as well as GSH biosynthesis and metabolism. The rapid advance of RNA sequencing technologies has contributed to the discovery of numerous non-coding RNAs with a wide range of functions. Recent lines of evidence show that several types of non-coding RNAs, including microRNA, long non-coding RNA and circular RNA, are abundantly expressed in the brain, and their activation or inhibition could contribute to neuroprotection through the regulation of GSH synthesis and/or metabolism. Interestingly, these non-coding RNAs play key roles in gene regulation and growing evidence indicates that non-coding RNAs interact with each other and are co-regulated. In this review, we focus on how the non-coding RNAs modulate the level of GSH and modify the oxidative stress states in the brain.

Keywords: glutathione; antioxidant; neuroprotection; long non-coding RNA; microRNA; circular RNA; oxidative stress; central nervous system

1. Introduction

The theory on the origin of life was first proposed by Russian biochemist Aleksandr Ivanovich Oparin [1]. According to his theory, the biological systems of the most primitive organisms may be much simpler than those of current life on Earth [2]. As the subsequent RNA World concept explained, RNA or RNA-like chemicals were likely to carry out most of the information processing and metabolic transformations needed for biology to emerge from chemistry in the early history of life [3,4]. This is consistent with the surprising finding in Tetrahymena that catalytic RNAs—i.e., ribozymes—carry out enzymatic functions similar to those carried out by proteins [5]. RNA can play several roles, including copying DNA and synthesizing proteins, functioning as a structural component of ribosomes and ribozymes and regulating various cellular processes [6]. It has long been considered that non-coding RNAs that cannot translate into a protein product are merely “junk” RNA [7]. However, such non-coding RNAs have become a hot topic in recent research [8]. It is increasingly becoming clear that many non-coding RNAs are in fact highly functional in biological systems and compensate for their inability to be translated into proteins through alternate mechanisms [9].
The evolution of primitive organisms might have been destined to proceed quite gradually in the primitive ocean. However, with the appearance of the first plants, known as cyanobacteria, and the initiation of photosynthesis by these organisms, the explosive evolution that is characteristic of life on this planet was begun [10]. On the other hand, adverse effects may have driven many of the primitive organisms to extinction because of the explosive increase of atmospheric oxygen [11]. The system of oxygen consumption thus contributed greatly to the evolution of biological species, but it also generated byproducts ROS that are highly toxic to living cells [12]. To protect themselves from ROS attack, surviving living beings internally acquired several distinct antioxidative defense systems [13,14]. Assuming that RNA was major molecules that regulate biological systems of life on Earth at that time, the fact that RNA can be easily changed or mutated might have made it ideal for rapid protective action against sudden ROS attack. In this regard, it is perhaps not surprising that several types of RNA make up some portions of antioxidant systems.

Neuroprotection against ROS attack in the central nervous system (CNS) is one of the most important goals of the antioxidant systems in animals with aerobic metabolisms, since the brain governs all organs of the body, including itself. In addition, the brain consumes more oxygen per unit of its weight than any other organ and contains numerous fatty acids that could be ROS targets for oxidization [15,16]. GSH is especially important in the brain, as evidenced by the fact that the levels of GSH in the brain are higher than the levels of other antioxidants, including catalase, superoxide dismutase (SOD) and glutathione peroxidase (GPx) [17,18]. An excess of ROS and/or depletion of antioxidants, which are defined as oxidative stress states, causes a number of clinically important diseases, including neurodegenerative diseases (NDs) [19]. Recently, several non-coding RNA studies in humans also revealed that the down-regulation and/or overexpression of non-coding RNAs is linked to diseases closely related to oxidative stress [20]. In this review, we focus on the regulatory mechanism of GSH neuroprotection by non-coding RNAs.

2. Antioxidants against Oxidative Stress

For the proper physiological activities of living beings, a balance is required between the levels of oxidants and antioxidants. An imbalance of redox states caused by an excess of oxidants, a depletion of antioxidants or both is defined as an oxidative stress state [21]. Oxidative stress has been implicated in the etiology of various diseases, such as NDs, cardiovascular diseases, chronic obstructive pulmonary disease, chronic kidney disease, obesity, and cancer [22]. On the other hand, ROS act as signaling molecules and play important roles in a variety of physiological functions, including the regulation of autophagy, immunity, and differentiation [23,24]. ROS are generated during the mitochondrial electron transport of aerobic respiration, as well as during cellular responses to xenobiotics, cytokines, and bacterial invasion [25]. ROS is a general term that includes molecules or ions formed by highly reactive and partially reduced oxygen metabolites [26].

2.1. Glutathione

One of the most important antioxidants is GSH, which is a tripeptide composed of three amino acids, cysteine, glutamate and glycine [27]. GSH is the major non-protein thiol distributed in most cells, and also functions as a storage and transport form of cysteine and an important player in antioxidative defense [27]. An excess amount of cysteine can be toxic to the cells because it induces free radical generation and extracellular glutamate production [28,29]. In addition, it has recently been reported that cysteine impairs mitochondrial respiration by limiting iron bioavailability through an oxidant-based mechanism [30]. GSH is a non-enzymatic antioxidant that acts as an impregnable defense against all forms of ROS [17]. In the brain, GSH is extremely important because the brain contains an abundance of lipids with unsaturated fatty acids that act as a source of peroxidation [31].

The biosynthesis of GSH occurs via a two-step ATP-requiring enzymatic process that is catalyzed by glutamate-cysteine ligase (GCL; also known as γ-glutamylcysteine...
GSH synthetase) and glutathione synthetase (GSS) (Figure 1) [17]. GCL catalyzes the formation of a dipeptide, \( \gamma \)-glutamylcysteine (\( \gamma \)-GluCys), from glutamate and cysteine, which is the rate-limiting step in GSH biosynthesis [32]. GCL is composed of a catalytic subunit (GCLc) and modulatory subunit (GCLm) [32,33]. GCLc possesses the enzymatic activity, while GCLm controls the kinetics of GCLc activity for GSH [34]. Mice with knockout of GCLm had as much as 70% depletion of brain GSH, which manifested only as mild abnormalities in neurons [35], while GCLc-knockout mice were embryonic lethal, and its conditional knockout of GCLc shows critical GSH depletion following neurodegeneration [36]. GSS is the enzyme in charge of the second step in GSH biosynthesis, which couples \( \gamma \)-GluCys with glycine to generate GSH [37]. Mice homozygous for GSS knockout died before embryonic day 7.5, while heterozygous mice survived with no distinct phenotype, probably because their GSH levels remained intact [38]. Cases of GCL or GSS deficiency in humans have been reported; these deficiencies are autosomal recessive metabolic disorders causing impaired physiological functions such as neuronal dysfunction and can cause mortality in early life [39].

\[ \text{Cys} \rightarrow \text{Cys}_2 \rightarrow \text{Glu} \rightarrow \text{Gly} \rightarrow \text{GSH} \]

Figure 1. Regulation of the redox system. Among the three amino acids that form GSH—i.e., cysteine (Cys), glutamate (Glu) and glycine (Gly)—Cys is the rate-limiting substrate. Cys is supplied via the Cys transporter EAAC1 or cystine (Cys\(_2\)) transporter system xc-\,. Cys\(_2\) is intracellularly reduced to Cys once imported into the cell, and turns out to be a building block of the antioxidant GSH. GSH synthesis is catalyzed by GCL and GSS. GSR transfers an electron from nicotinamide adenine dinucleotide phosphate (NADPH) to GSSG, and thereby catalyzes the reduction of GSSG to GSH. GPx reduces peroxide (R-OOH) to a harmless compound (R-OH) by gathering the needed reducing equivalents from GSH. SOD converts superoxide anion to less noxious hydrogen peroxide (H\(_2\)O\(_2\)), and catalase (CAT) reduces H\(_2\)O\(_2\) without any activator.

Once GSH acts as an electron donor, a disulfide bond is formed to produce oxidized glutathione (GSSG) [40]. GSSG is a substrate of the flavoenzyme glutathione reductase (GSR), which transfers an electron from nicotinamide adenine dinucleotide phosphate (NADPH) to GSSG, thereby regenerating GSH and establishing a system for recycling GSH [41]. On the other hand, glutathione-S-conjugation by glutathione-S-transferases (GST) consumes GSH [42]. GSH-conjugated compounds are actively pumped out of the cell by numerous members of the multidrug resistance-associated protein (MRP) family [43–46].
2.2. Antioxidant Enzymes

SOD and catalase as well as GPx are enzymes that have a protective effect against oxidative stress (Figure 1) [47]. SOD plays a role in converting superoxide anions to less noxious hydrogen peroxide [48]. Both catalase and GPx effectively disproportionate hydrogen peroxide into harmless water and oxygen [49,50]. While catalase does not require any activator, GPx requires GSH for its activity as an electron donor. The formation of a disulfide bond between two GSH molecules gives rise to GSSG in the GPx-catalyzed reaction [50].

Three types of SOD have been identified. SOD2 (also known as MnSOD) is mainly expressed in the mitochondria and requires manganese ion for its activation. SOD1 (also known as Cu/ZnSOD) and SOD3 (also known as ECSOD), which require copper and zinc ion, are respectively expressed intracellularly and extracellularly [51,52]. It has been well established that mutations of the SOD1 gene are implicated in the etiology of amyotrophic lateral sclerosis (ALS), one of the NDs [53]. A hallmark of SOD1-associated ALS is the deposition of SOD1 into insoluble aggregates in motor neurons, probably as a result of mutation-induced structural destabilization and/or oxidative damage because of mutation, which in turn contributes to the misfolding and aggregation of SOD1 into neurotoxic species [54].

Catalase is a heme-containing homotetrameric protein without any isoforms. Mice lacking catalase develop normally, although catalase deficiency or mutation in humans results in acatalasemia, which is characterized by oral gangrene, altered lipid, carbohydrate, and homocysteine metabolism and an increased risk of diabetes mellitus, although there are only limited reports of acatalasemia in the literature [55–58].

Eight isoforms of GPx have been identified, GPx1 to GPx8 [59]. GPx1-4 are selenium-dependent enzymes, whereas GPx5, GPx7 and GPx8 are selenium-independent but contain a cysteine instead of a selenocysteine [50]. GPx1 is the most abundant cellular GPx and functions as an important antioxidant enzyme that interacts with fatty acid hydroperoxides as well as hydrogen peroxide in the brain. On the other hand, GPx2 and GPx3 have been identified as gastrointestinal and plasma GPx isoforms, respectively. GPx4 is a ubiquitously expressed peroxidase that can directly reduce lipid hydroperoxides in the cellular membrane [60]. GPx5 is an epididymal-specific secretory GPx, and GPx6 is expressed in the olfactory epithelium. GPx7 and GPx8 have been observed in the lumen and membrane of the endoplasmic reticulum (ER), respectively. Studies using GPx1-knockout mice showed that these animals were phenotypically normal, but they were particularly susceptible to oxidative stress in the brain [61–63]. Although homozygotes of GPx4-knockout mice are embryonic lethal, heterozygous mice do not show any alterations in the activities of other major antioxidant defense enzymes, such as Gpx1 and catalase [64,65]. However, it has been determined that Gpx4 heterozygotes show increased lipid peroxidation in the brain [66].

2.3. Glutaredoxin, Thioredoxin and Peroxiredoxin

Glutaredoxins (Grxs), thioredoxins (Trxs) and peroxiredoxins (Prxs) have been characterized as electron donors, and shown to function in the protection of the intracellular redox state and as antioxidants [67,68]. Both Grxs and Trxs are members of a superfamily of low-molecular-mass proteins that catalyze the reduction of disulfide bonds in a variety of proteins. GSSG formed in the Grx reaction is reduced by GSR at the expense of NADPH, whereas oxidized Trx is reduced by thioredoxin reductase (TrxR) with electrons transferred from NADPH [69]. Prxs are peroxidase enzymes that receive electrons from NADPH by coupling with Trx and TrxR [70].

2.4. The Nrf2-Keap1 System

Nuclear factor erythroid 2-related factor 2 (Nrf2) is one of the most important transcriptional factors, with a responsibility for regulating hundreds of antioxidant genes involved in the synthesis, metabolism and conjugation of GSH [71]. Kelch-like ECH-associated
protein1 (Keap1) has been identified as a factor that negatively regulates Nrf2. Under normal conditions, Keap1, which forms a ubiquitin E3 ligase complex with Cullin3, binds to Nrf2, trapping Nrf2 into the cytosol and promoting its ubiquitination and proteasomal degradation. On the other hand, oxidative stress conditions modify the cysteine residues of Keap1, facilitating the dissociation of Nrf2 from Keap1, which promotes the nuclear translocation of Nrf2. In the nucleus, Nrf2 heterodimerizes with small musculo-aponeurotic fibrosarcoma (sMAF) and interacts with antioxidant response elements (ARE) in the promoter region of target genes, resulting in their transcriptional activation [72]. Krüppel-like factor 2 (KLF2) is a member of the zinc finger transcription factor family and acts to prime Nrf2 activation through enhanced nuclear localization [73]. Nrf2 transcriptionally regulates several antioxidant genes, including GCLc, GCLm, GSS, GPx4, GSR, Trx1, TrxR and catalase, some of which are also up-regulated by KLF2 [74]. Nrf2-knockout mice lose the ability to induce antioxidative genes such as GPx, SOD, GST, and catalase, with the result that the GSH system for protection against oxidants is not induced, and the mice are left vulnerable to oxidative stress [75,76].

3. Uptake System for the Sources of GSH

3.1. Cysteine Uptake System

Although GSH is composed of three amino acids, the determinant substrate for neuronal GSH synthesis is cysteine [37]. Cysteine uptake in neurons is mostly mediated by sodium-dependent systems, mainly the excitatory amino acid carrier 1 (EAAC1; also known as EAAT3 or SLC1A1) (Figure 1) [77]. EAAC1 is one of the five excitatory amino acid transporters (EAATs) that are collectively known as solute carrier family 1 (SLC1). EAAC1-deficient mice exhibit an approximately 40% decrease in brain GSH content and neurodegeneration in advanced age [77]. Further, overexpression of Nrf2 in brain neurons is sufficient to upregulate both neuronal EAAC1 protein and GSH content, and these effects were abrogated in mice genetically deficient in either Nrf2 or EAAC1 [78]. EAATs are responsible for the uptake of glutamate; the known EAATs include glutamate aspartate transporter (GLAST; also known as EAAT1 or SLC1A3), glutamate transporter-1 (GLT-1; also known as EAAT2 or SLC1A2), EAAC1, EAAT4 (also known as SLC1A6) and EAAT5 (also known as SLC1A7) [79]. The EAATs are secondary active transporters, translocating three sodium ions and one proton and counter-transporting one potassium ion for each substrate, and thereby supplying the energetic driving force to transport glutamate against its electrochemical gradient [80]. Recent lines of evidence show that cysteine transport through EAAC1 is facilitated through cysteine deprotonation and that, once inside, the thiolate is rapidly reprotonated [81,82]. GLAST and GLT-1 are expressed in astrocytes, whereas EAAC1, EAAT4 and EAAT5 are expressed in neurons [83]. EAAC1 and GLT-1 are widely distributed throughout the brain, although the distribution of GLAST, EAAT4 and EAAT5 is restricted.

3.2. Cystine Uptake System

In the extracellular environment, cysteine is mainly present in its oxidized form, cystine [84]. Cystine is intracellularly reduced to cysteine once imported into the cell, and turns out to be a building block of the antioxidant GSH [85]. Cystine transport is mediated via system xc−, which is composed of a heavy chain subunit 4F2hc (encoded by the SLC3A2 gene) and a light chain specific subunit xCT (encoded by the SLC7A11 gene). System xc− exchanges glutamate for cystine in a 1:1 ratio according to the respective concentration gradients. Investigation into the localization of system xc− at the cellular level in the brain using immunohistochemistry in rat brain slices showed that system xc− is localized mainly in astrocytes, but not in neurons [86]. In addition, the inflammatory stimulation specifically upregulates system xc− activity in astrocytes but not in microglia and neurons [86–89]. However, another study using immunohistochemistry showed that xCT was localized in both neurons and astrocytes in the mouse and human brain [90]. Since deficiency of EAAC1 in mice results in a significant decrease in brain GSH content but not zero brain...
GSH content [77], system xc- may also play a small role in uptake of the sources of GSH in neurons.

Ferroptosis is a recently described form of non-apoptotic regulated cell death caused by iron-dependent lipid peroxidation that is distinct in its morphological and genetic profile from other cell death mechanisms such as apoptosis, necroptosis, or autophagy [91]. GPx4 was identified as a key regulatory factor in ferroptosis, the process of detoxifying membrane lipid peroxidation by converting lipid peroxides to non-toxic lipids [92,93]. GSH is a cofactor for GPx4 and is required for the detoxification of lipid peroxidation [94]. Inhibition of system xc- caused cysteine depletion, resulting in a lack of GSH synthetic substrate, leading to impairment of GPx4 function and finally ferroptosis [95,96]. Further, GPx4 inhibition via Ras-selective lethal small molecule 3 or genetic knockdown of GPx4 could also induce ferroptosis [96].

4. Neuroprotective Function of Non-Coding RNA

Soon after DNA was determined to be the store of genetic information in the eukaryotic nucleus, and after proteins were shown to be synthesized in the cytoplasm based on this information, RNA was first recognized in the form of the messenger (mRNA) that passed genetic information from the DNA to the protein synthetic machinery as explained in the classical central dogma of molecular biology [97]. Then, the functional RNAs, i.e., transfer RNA (tRNA) and ribosomal RNA (rRNA), were found to be involved in protein synthesis. Sometime later, several small non-mRNAs, other than rRNA and tRNA, were detected and isolated with associating ribonucleoprotein (RNP) complexes. These short non-coding RNAs play an essential role in the maturation of functional RNAs, which are small nuclear RNAs (snRNAs) involved in splicing events and small nucleolar RNAs (snoRNAs) guiding posttranscriptional modifications on rRNAs and snRNAs [97,98].

Recently, several classes of regulatory non-coding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and so on, have been discovered to act as key regulators of gene expression in many different cellular pathways and systems [99]. These different types of non-coding RNAs are found to confer neuroprotection against oxidative stress by linking with each other [20].

4.1. MicroRNAs

MicroRNAs (miRNAs), which are a class of short non-coding RNAs approximately 20 nucleotides in length, are among the most well-studied ncRNAs [100]. The function of miRNAs is mainly to silence target expressions by binding to target gene transcripts located mainly at the 3′-untranslated regions (3′-UTR). Clustered miRNAs can either be simultaneously transcribed from single polycistronic transcripts containing multiple miRNAs or independently transcribed. In most cases, RNA polymerase II transcribes the primary miRNAs (pri-miRNAs), which are cleaved by a complex called a microprocessor, which contains the ribonuclease III Drosha and the RNA-binding protein DGCR8/Pasha, to generate small hairpin-shaped RNAs, called miRNA precursors (pre-miRNAs). Pre-miRNAs are exported by exportin-5 in complex with RAN-GTP and are processed by a double-stranded ribonuclease III enzyme termed Dicer, which is complexed with TRBP. The mature miRNA duplexes are loaded onto an Argonaute protein to form an effector complex called the RNA-induced silencing complex (RISC). Finally, one strand of the miRNA is removed from RISC to generate the mature RISC that induces gene silencing. The post-transcriptional regulation by the RISC complex is mediated by incomplete base-paring of miRNA-mRNA interactions, likely due to the targeting of multiple transcripts, which contributes to the complexity or redundancy of miRNA systems.

Numerous miRNAs have been identified as regulators of GSH-regulating factors. Several reports have shown that GSH or ROS levels are modulated by miRNAs through the regulation of factors related to GSH synthesis and/or metabolism in the brain or neuronal cells. Among them, the Nrf2-mediated pathway has been well-studied in relation to the regulation of neuroprotection and oxidative stress (Figure 2). MiR-23a-3p targets Nrf2 itself,
and injection of antagomiR into the lateral ventricle results in an increase of GPx4 expression and an inhibition of ROS accumulation and lipid peroxidation in a rat model of intracerebral hemorrhage [101]. In addition, hydrogen peroxide-responsive miR-153 directly targets and inhibits gene expression of Nrf2, which results in ROS accumulation by preventing transactivation of the downstream antioxidant gene GCLc [102]. On the other hand, miR-7 can activate the Nrf2 pathway by directly targeting the 3'-UTR of Keap1 mRNA to increase GSH levels by inducing an increase in GCLm expression [103]. Nrf2 activator KLF2 is targeted by miR-25, and this action results in an inhibition of proliferation while promoting the apoptosis of hippocampal neurons with a reduction of GSH level and antioxidant enzyme expression [104]. It has also been reported that the inhibition of miR-592 function promotes an increase in GSH levels and a decrease of ROS via an Nrf2-signaling pathway by up-regulating KIAA0319, which is a dyslexia-associated protein [105,106]. An Nrf2-signaling pathway is also modulated by miR-139 or miR-144, both of which have been shown to modulate redox states, although the precise mechanisms by which they modulate the Nrf2-signaling pathway remain unknown [107,108]. The PI3K/Akt pathway plays key roles in regulating Nrf2-dependent protection against oxidative stress (Figure 2). Downregulation of miR-200c-3p increases GSH and SOD levels and reduces the damage to hippocampal neurons by upregulating the reversion-inducing-cysteine-rich protein with kazal motifs (RECK) and inactivating the Akt signaling [109]. Inhibition of miR-204-5p alleviated oxidative injuries in hippocampal neuronal cells via a reduction of ROS and oxidative stress marker malondialdehyde (MDA) levels and an upregulation of SOD and GSH, possibly by targeting brain-derived neurotrophic factor (BDNF) in the neurotrophic tyrosine kinase receptor type 2 (TrkB)-mediated pathway [110]. Upregulation of miR-409 expression activates the Akt-regulated glycogen synthase kinase 3β (GSK3β), leading to an increase in GSH and SOD levels and decrease in ROS levels, which protects against ROS-induced neurotoxicity [111]. MiR-214 plays a neuroprotective role characterized by an increase of SOD and GSH levels directly targeting phosphatase and tensin homolog deleted from chromosome 10 (PTEN), a suppressor of Akt signaling [112]. The mitogen-activated protein kinase (MAPK) pathway is also important because MAPKs such as ERK, p38MAPK and JNK are downstream effectors of antioxidant responses and changes in GSH levels (Figure 2). MiR-410 promotes decreased MDA content but increased SOD activities and GPx activities in hippocampal neurons by regulating the p38/JNK pathway through the inhibition of tissue inhibitors of metalloproteinase 2 (TIMP2) [113]. Induction of miR-486 by ROS generation inhibits NeuroD6 expression in the p38/JNK pathway, resulting in increased content of SOD and GPx, as well as reduced MDA content [114]. The upregulation of miR-136 could potentially inhibit inducible nitric oxide synthase (iNOS) activation as well as the apoptosis of neurons by negatively targeting Kallikrein-related peptidase 7 (KLK7) through inhibition of the p38 signaling pathway, resulting in increased content of SOD and GPx, as well as reduced MDA content [115]. Other signaling pathways are also cross-linked and interact with each other to regulate intracellular GSH levels. MiR-146a has a protective effect in the brain by repressing the tumor necrosis factor receptor associated factor (TRAF6)-mediated nuclear factor kappa B (NF-κB) pathway, leading to inhibition of inflammation and oxidative stress [116]. MiR-98 improves oxidative stress and mitochondrial dysfunction through activation of the Notch signaling pathway by binding to Hairy/enhancer-of-split related with YRPW motif protein 2 (HEY2) with enhancement of viability in hippocampal neurons [117]. Overexpression of miR-129-3p can alleviate oxidative stress and ROS-mediated apoptosis of hippocampal neurons by targeting mitochondrial calcium uniporter (MCU) [118]. The suppression of miR-200a can inhibit apoptosis in striatal neuron cells, increase the levels of GSH and SOD and decrease the level of MDA in the brain tissue by upregulating dopamine receptor D2, and thereby, repressing the cAMP/PKA signaling pathway [119]. MiR-320 affects cellular proliferation, apoptosis, and oxidative stress by inhibiting the NADPH oxidase 2 (Nox2) pathway [120]. EAAC1 is negatively regulated by miR-96-5p, and blocking of miR-96-5p by the administration of an inhibitor increased the levels of EAAC1 and GSH and had
a neuroprotective effect against oxidative stress in the mouse substantia nigra [121]. In addition, miR-96-5p can indirectly regulate GTRAP3-18, a negative regulator of EAAC1, through directly targeting RNA-binding protein NOVA1 and modulate the levels of GSH in the mouse dentate gyrus of hippocampus as well as SH-SY5Y cells [122]. Multidrug resistance-associated protein 1 (MRP1), which is a direct target of miR-199a-5p, plays a key role in clearing intracellular GSSG [123]. These reports indicate that up- or down-regulation of miRNA function can modulate GSH levels and thereby regulate the neuroprotective effects of GSH (Table 1).

Figure 2. Signal transduction related to transactivation of antioxidative genes regulated by ncRNAs. Nrf2 is a transcriptional factor that enters the nucleus in response to oxidative stress, resulting in increased expression of numerous neuroprotective genes. Nrf2 is regulated through the PI3K/Akt pathway, which plays key roles in regulating neuroprotection against oxidative stress. BDNF is a ligand of TrkB, which promotes neuronal survival and protects against apoptosis mediated through the PI3K/Akt pathway. BDNF can also bind to p75NTR—which was identified as a low-affinity nerve growth factor receptor—and BDNF can activate the NFkB pathway as well as the p38/JNK pathways. Boxes indicate miRNAs that target the signal transduction molecule, and the rounded rectangle indicates lncRNA.

Table 1. List of miRNAs regulated redox states in brain tissue or neuronal cells.

| MiRNA    | Direct Target | Related Pathway | Effect on Redox States | Brain Tissue or Neuronal Cell | Ref  |
|----------|---------------|----------------|------------------------|-------------------------------|------|
| miR-7    | Keap1         | Nrf2 pathway   | GSH ↑, GCLm ↑, CBA ↓  | SH-SY5Y cell                 | [103]|
| miR-23a-3p| Nrf2          | Nrf2 pathway   | n.d.                   | brain                         | [101]|
| miR-25   | KLF2          | Nrf2 pathway   | GSH ↓, GST ↓, Trx ↓ | hippocampus                   | [104]|
| miR-96-5p| EAAC1         | Cys transport  | GSH ↓, n.d.            | substantia nigra              | [121]|
| miR-96-5p| NOVA1         | Cys transport  | GSH ↓, n.d.            | dentate gyrus of hippocampus  | [122]|
| miR-98   | HEY2          | Notch signaling| GSH ↑, GPx ↑, SOD ↓   | hippocampus                   | [117]|
| miR-129-3p| MCU           | MMP2 pathway   | GSH/GSSG ↓, SOD ↓, ROS ↑| primary hippocamal neurons    | [118]|
|          |               |                |                        |                               |      |
Table 1. Cont.

| MiRNA          | Direct Target Related Pathway | Effect on Redox States | Brain Tissue or Neuronal Cell | Ref   |
|----------------|-------------------------------|------------------------|-------------------------------|-------|
| miR-139        | n.d.                          | GSH ↑, CAT ↑, SOD ↑, MDA ↓ | SH-SYSY cell                 | [107] |
| miR-144        | n.d.                          | GSH ↓, GPx ↓, ROS ↑, MDA ↓ | SH-SYSY cell                 | [108] |
| miR-146a       | TRAF6                         | GSH ↓, GPx ↑, SOD ↑, MDA ↓ | brain                        | [116] |
| miR-153        | Nrf2                          | GSH ↑, CAT ↑, SOD ↑, MDA ↓ | SH-SYSY cell                 | [102] |
| mir-199a-5p    | MRP1                          | GSSG ↑, GPx ↑, SOD ↑, MDA ↓ | primary cortical neurons     | [123] |
| miR-200a       | n.d.                          | GPx ↓, SOD ↓, MDA ↑    | striatum                     | [119] |
| miR-200c-3p    | RECK                          | GPx ↓, SOD ↓, MDA ↑    | hippocampus                  | [109] |
| miR-204-5p     | BDNF                          | GSH ↓, SOD ↓, ROS ↑, MDA ↑ | HT-22 cell                   | [110] |
| mir-214        | PTEN                          | GSH ↑, SOD ↑, MDA ↓    | SH-SYSY cell                 | [112] |
| miR-320        | Nox2                          | GPx ↑, CAT ↑, SOD ↑, MDA ↓ | primary neuron               | [120] |
| miR-326        | KLK7                          | SOD ↓, GPx ↓, MDA ↑    | striatum                     | [115] |
| miR-409        | n.d.                          | GSH ↑, SOD ↑, ROS ↓    | PC-12 cell                   | [111] |
| miR-410        | TIMP2                         | GPx ↑, SOD ↑, MDA ↓    | hippocampal neurons          | [113] |
| miR-486        | NeuroD6                       | GPx ↓, ROS ↑           | spinal cord                  | [114] |
| miR-592        | KIAA0319                      | GSH ↓, CAT ↓, SOD ↓, MDA ↑ | cortical astrocytes          | [105] |

Upward and downward arrows indicate increased and decreased level of redox markers, respectively. *1 Area of brain tissue were not specified in the article. *2 CBA: Coumarin boronate acid. n.d.; not detected.

4.2. Long Non-Coding RNAs

Long non-coding RNAs (lncRNAs) are long RNA transcripts that are not protein-coding, and are longer than 200 nucleotides by definition [124]. The transcription for lncRNAs is transcribed by RNA polymerase II, similar to the transcription for mRNAs, as they are capped, spliced and polyadenylated, however, lncRNAs lack a translated open reading frame. LncRNA is a quite heterogenous term, in the sense that it encompasses several functionally different types of lncRNAs that have different biogenetic mechanisms. LncRNAs are roughly classified based on their position relative to protein-coding genes: exon or intron sense-overlapping, intergenic, antisense, bidirectional and enhancer lncRNAs [124]. Functionally, lncRNAs can guide transcription factors to specific genomic locations for the regulation of gene expression, work as a scaffold to facilitate the assembly of chromatin remodeling complexes, serve as a sponge to titrate miRNAs out from their mRNA targets, or bind to transcription factors or other proteins as a decoy and sequester them away from chromatin [124]. Some lncRNAs play a role in neuroprotection mostly by modulating the expression of miRNAs by acting as their sponge [20] (Figure 3).

Nuclear paraspeckle assembly transcript 1 (NEAT1, an lncRNA) is transcribed from familial tumor syndrome multiple endocrine neoplasia (MEN) type 1 and encodes two transcriptional variants. NEAT1 acts as a sponge for miR-1277-5p targeting Rho GTPase activating protein 26 (ARHGAP26), resulting in oxidative stress with a reduction of GPx and SOD activities in cells of the neuroblastoma cell line, SK-N-SH [125]. LncRNA plasmacytoma variant translation 1 (PVT1) is an intergenic lncRNA with multiple splice isoforms. PVT1 has been reported to regulate ferroptosis through miR-214-mediated p53, upregulation of which markedly reduced the expressions of xCT and GPx4 in SK-N-SH cells [126]. LncRNA AK046177 appears to be transcribed from the loci at the protein encoding region of poly (ADP-ribose) polymerase family, member 8 (Parp 8). Downregulations of AK046177 and miR-134, along with increasing intracellular cAMP levels and activation of the Nrf2 pathway leading to reductions of ROS and increases of SOD and GPx activities thereby protecting the brain [127]. LncRNA H19 is a maternally expressed...
and paternally imprinted gene located near the telomeric region adjacent to the insulin like growth factor 2 (IGF2) gene [128]. H19 acts as a sponge for miR-148a-3p, which could target Rho associated coiled-coil containing protein kinase 2 (ROCK2), such that inhibition of H19 has a neuroprotective effect to increase SOD and GPx activities while decreasing ROS level [129]. There is another report about lncRNA H19 which shows that downregulation of H19 suppresses hippocampal neuron apoptosis by inhibiting IGF2 methylation [130]. When the lncRNA gene is an antisense gene that overlaps the genomic coordinates of a protein-coding gene on the opposite strand, the lncRNA genes are named as protein-coding gene symbol with the suffix -AS and sequential number. β-secretase 1 antisense RNA (BACE1-AS) downregulates its antisense coding protein BACE1 by down-regulation of miR-34b-5p, and down-regulation of BACE1-AS improves dopamine-dependent oxidative stress by inhibition of iNOS activation in the substantia nigra [131]. Further, Wilms’ tumor 1 antisense RNA (WT1-AS) suppresses the expression of WT1 by acting as an miR-375 sponge and plays a neuroprotective role in SH-SY5Y cells [132]. Silencing of lncRNA SRY-Box transcription factor 21 (SOX21) antisense divergent transcript 1 (SOX21-AS1) could act to alleviate neuronal oxidative stress and suppress neuronal apoptosis through the upregulation of Frizzled3/5 (FZD3/5) and subsequent activation of the Wnt signaling pathway in hippocampal neurons [133]. These results suggest that activation or inactivation of lncRNA contributes to neuroprotection mainly by allowing IncRNA to act as a functional miRNA sponge (Table 2).

![Figure 3. Interplay of lncRNAs and miRNAs in neuroprotective effect. LncRNAs play a key role in neuroprotection mainly by acting as a miRNA sponge. Boxes indicate miRNAs that target the signal transduction molecule, and the rounded rectangle indicates lncRNAs.](image-url)
Table 2. List of lncRNAs regulated redox states in brain tissue or neuronal cell.

| LncRNA     | Direct Target | Function                                                                 | Effect on Redox States | Brain Tissue or Neuronal Cell | Ref   |
|------------|---------------|--------------------------------------------------------------------------|------------------------|--------------------------------|-------|
| AK046177   | n.d.         | Nrf2/CREB regulation acting with miR-134                                  | n.d.                  | GPx ↓ SOD ↓ ROS ↑ MDA ↑       | primary cortical cell | [127] |
| BACE1-AS   | miR-34b-5p    | BACE1 upregulation acting as miR-34b-5p sponge                            | n.d.                  | GPx ↓ SOD ↓ MDA ↑             | substantia nigra    | [131] |
| H19        | miR-148a-3p   | ROCK2 upregulation acting as miR-148a-3p sponge                           | n.d.                  | GPx ↓ SOD ↓ MDA ↑             | Neuro2a cell        | [129] |
| H19        | IGF2         | Inhibition of antioxidative gene transcription ARHGAP26                   | GSH ↓                 | GPx ↓ CAT ↓ SOD ↓             | hippocampal neuron  | [130] |
| NEAT1      | miR-1277-5p  | Upregulation acting as miR-1277-5p sponge                                 | n.d.                  | GPx ↓ SOD ↓ MDA ↑             | SK-N-SH cell        | [125] |
| PVT1       | miR-214-3p   | Upregulation acting as miR-1277-5p sponge                                 | GSH ↑                 | GPx ↑ MDA ↓                   | SK-N-SH cell        | [126] |
| SOX21-AS1  | FZD3/5       | Inactivation of Wnt signaling pathway                                     | n.d.                  | GPx ↓ CAT ↓ SOD ↓ ROS ↑ MDA ↑ | 4-HNE ↑           | hippocampal neuron  | [133] |
| WT1-AS     | miR-375      | 4-HNE ↑                                                                   | n.d.                  | GPx ↑ SOD ↑ ROS ↓ MDA ↓       | SH-SY5Y cell        | [132] |

Upward and downward arrows indicate increased and decreased level of redox markers, respectively. * 4-HNE: 4-hydroxy-2-nonenal. n.d.; not detected.

4.3. Circular RNAs

Circular RNAs (circRNAs) are single-stranded RNAs that form circular molecules in which the 3′ and 5′ ends are covalently linked [134]. The classic regulatory mechanisms of circRNAs involve their role as competitive endogenous RNAs (ceRNAs). CircRNAs can regulate gene expression by influencing transcription, mRNA turnover, and translation by sponging RNA-binding proteins and miRNAs. A search on PubMed uncovered no reports of specific circRNAs modulating the levels of GSH or oxidative stress specifically in the brain or neuronal cells. However, most of the miRNAs that can modulate GSH levels, which are listed in Table 1, have been reported to be regulated by several circRNAs. For example, CDR1as (also named ciRS-7 or CDR1NAT), which is formed by reverse splicing of the antisense strand of the cerebellar degeneration-associated antigen 1 (CDR1) gene [135], has more than 70 miR-7-binding sites that inhibit its binding to target genes [134]. As described above, miR-7 targets Keap1 to regulate and modulate the neuroprotective effects of GSH [103].

There are some reports that have shown that circRNAs modulate protective effects against cellular damage, although these effects are not related to neurons or the brain (Figure 4). Knockdown of circRNA_0084043 remarkably reduced oxidative stress as evidenced by the down-regulated MDA content, enhanced activities of SOD and GPx via sponging of miR-140-3p and regulation of transforming growth factor alpha (TGFA) in a hyperglycemia-induced human retinal pigment epithelial cell, ARPE-19 [136]. Up-regulation of circHIPK3 or down-regulation of circHIPK3 targeting miR-221-3p mediated the promotion of proliferation, inhibition of apoptosis, decrease of MDA level and increase of GPx level in human lymphatic endothelial cells [137]. CircHIPK3 also inhibits proliferation and induces apoptosis of cardiomyocytes via binding to miRNA-124-3p in human cardiac myocytes (HCM) [138]. CircRNA_0001445 inhibits oxidized LDL-induced inflammation, oxidative stress and apoptosis by regulating miRNA-640 in human umbilical vein endothelial cells (HUVECs) [139]. CircIL4R acts as a miR-541-3p sponge to regulate its target GPx4, the upregulation of which relieved the miR-541-3p-induced tumor inhibition and ferroptosis aggravation in hepatocellular carcinoma [140]. CircEPSTI1 attenuates the effects of ferritin, which are mediated by xCT, which in turn regulates lipid peroxidation...
and GSH levels in cervical cancer [141] (Table 3). Further research will shine light on the contribution of circRNAs to the neuroprotective effects of GSH.

Figure 4. Interplay of circRNAs and miRNAs in cellular protective effect. CircRNAs play a key role in protective function mainly by acting as a miRNA sponge. Boxes indicate miRNAs that target the signal transduction molecule, and the oval indicates circRNAs.

Table 3. List of circRNAs regulated redox states in tissue or cell.

| CircRNA    | Direct Target | Function                                                                 | Glutathione | Antioxidative Enzymes | Oxidative Stress | Tissue or Cell | Ref    |
|------------|---------------|--------------------------------------------------------------------------|-------------|-----------------------|------------------|----------------|--------|
| circRNA_0084043 | miR-140-3p    | TGFA upregulation acting as miR-221-3p sponge PI3K/AKT pathway activation | n.d.        | GPx ↓ SOD ↓           | MDA ↑            | ARPE-19 cells  | [136]  |
| circHIPK   | miR-221-3p    | apoptosis induction acting as miR-140-3p sponge                            | n.d.        | GPx ↑                 | MDA ↓            | LECs           | [137]  |
| circHIPK   | miR-124-3p    | apoptosis induction acting as miR-124-3p sponge                            | n.d.        | GPx ↓ SOD ↓           | MDA ↑ LDH Δ*†    | HCM            | [138]  |
Table 3. Cont.

| CircRNA      | Direct Target | Function                              | Effect on Redox States                      | Tissue or Cell       | Ref  |
|--------------|---------------|---------------------------------------|---------------------------------------------|----------------------|------|
| circRNA_0001445 | miR-640       | protective function acting as miR-640 sponge GPx upregulation | n.d. GPx ↑ SOD ↑ MDA ↓ | HUVECs [139]         |      |
| circIL4R     | miR-541-3p    | GPx4 upregulation acting as miR-541-3p sponge | n.d. n.d. ROS ↓ MDA ↓ | hepatocellular carcinoma [140] |      |
| circEPSTI1   | miR-375       | upregulation acting as sponge of miR-375, -409-3p and -515-5p | GSH/GSSG ↑ | Liperfluo *2 ↓ | cervical cancer [141] |
|              | miR-409-3p    |                                        |                                             |                      |      |
|              | miR-515-5p    |                                        |                                             |                      |      |

Upward and downward arrows indicate increased and decreased level of redox markers, respectively. *1 LDH: lactate dehydrogenase, *2 Liperfluo: N-(4-Diphenylphosphinophenyl)-N′-(3,6,9,12-tetraoxatridecyl) perylene-3,4,9,10-tetracarboxydiimide. n.d.; not detected.

5. Conclusions

A novel class of non-coding RNAs is increasingly being identified along with the evolution of RNA technologies. These RNAs appear to regulate gene expression by linking and interacting with each other. Recently, abnormalities in the expression of these non-coding RNAs have been reported to be involved in the cause and/or progress of several diseases, including NDs. As described in this review, several types of non-coding RNAs have been reported to contribute to the regulation of GSH synthesis and/or metabolism in various cell lines and tissues. Since GSH depletion has long been observed in patient with NDs, it may be that the etiology of NDs involves oxidative stress induced by alterations in the expression of non-coding RNAs. This is a meaningful indication that modulation of the expression of non-coding RNAs could be a novel therapeutic approach for NDs via an increase in GSH levels. Recently, some of the miRNA-based therapeutics are actually processed in preclinical and clinical trial for various diseases including NDs. Understanding the interplay of miRNAs and other non-coding RNAs is key for the development of next generation drugs for the cure of NDs.

Author Contributions: Conceptualization, C.K. and K.A.; writing, C.K.; supervision, K.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ROS Reactive oxygen species
GSH Glutathione
CNS Central nervous system
SOD Superoxide dismutase
GPx Glutathione peroxidase
ND Neurodegenerative disease
H₂O₂ Hydrogen peroxide
NO Nitric oxide
NOS Nitric oxide synthase
GCL Glutamate-cysteine ligase
GSS Glutathione synthetase
γ-GluCys γ-glutamylcysteine
GCLc Catalytic subunit of glutamate-cysteine ligase
GCLm Modulatory subunit of glutamate-cysteine ligase
| Acronym | Description |
|---------|-------------|
| GSSG    | Oxidized glutathione |
| GSR     | Glutathione reductase |
| NADPH   | Nicotinamide adenine dinucleotide phosphate |
| GST     | Glutathione-S-transferase |
| MRP     | Multidrug-resistance-associated protein |
| γ-GT    | γ-glutamyltranspeptidase |
| CysGly  | Cysteinylglycine |
| Glycys  | Glycylcysteine |
| ALS     | Amyotrophic lateral sclerosis |
| Grx     | Glutaredoxin |
| Trx     | Thioredoxin |
| Prx     | Peroxiredoxin |
| TrxR    | Thioredoxin reductase |
| Nrf2    | Nuclear factor erythroid 2-related factor 2 |
| Keap1   | Kelch-like ECH-associated protein 1 |
| sMAF    | Small Musculo-aponeurotic fibrosarcoma |
| ARE     | Antioxidant response element |
| KLF2    | Krüppel-like factor 2 |
| EAAC1   | Excitatory amino acid carrier 1 |
| EAAT    | Excitatory amino acid transporter |
| SLC1    | Solute carrier family 1 |
| GLAST   | Glutamate aspartate transporter |
| GLUT-1  | Glutamate transporter-1 |
| mRNA    | Messenger RNA |
| tRNA    | Transfer RNA |
| rRNA    | Ribosomal RNA |
| snRNA   | Small nuclear RNA |
| snoRNA  | Small nucleolar RNA |
| miRNA   | MicroRNA |
| 3’-UTR  | 3’-untranslated region |
| Pri-miRNA | Primary microRNA |
| Pre-miRNA | MicroRNA precursor |
| RISC    | RNA-induced silencing complex |
| RECK    | Reversion-inducing-cysteine-rich protein with kazal motifs |
| MDA     | Malondialdehyde |
| BDNF    | Brain-derived neurotrophic factor |
| TrkB    | Tyrosine kinase receptor type21 |
| GSK3β   | Glycogen synthase kinase 3β |
| PTEN    | Phosphate and tensin homolog deleted from chromosome 10 |
| MAPK    | Mitogen-activated protein kinase |
| ERK     | Extracellular signal-regulated kinase |
| JNK     | c-Jun N-terminal protein kinase |
| TIMP2   | Tissue inhibitors of metalloproteinase 2 |
| iNOS    | Inducible nitric oxide synthase |
| KLK7    | Kallikrein-related peptidase 7 |
| TRAF6   | Tumor necrosis factor receptor associated factor 6 |
| NF-κB   | Nuclear factor kappa B |
| HEY2    | Hairy/enhancer-of-split related with YRPW motif protein 2 |
| MCU     | Mitochondrial calcium uniporter |
| Nox2    | Nicotinamide adenine dinucleotide phosphate oxidase 2 |
| lncRNA  | Long non-coding RNA |
| NEAT1   | Nuclear paraspeckle assembly transcript 1 |
| MEN     | Multiple endocrine neoplasia |
| ARHGAP26| Rho GTPase activating protein 26 |
| Parp8   | Poly (ADP-ribose) polymerase family, member 8 |
| IGF2    | Insulin like growth factor 2 |
| ROCK2   | Rho associated coiled-coil containing protein kinase 2 |
References

1. Oparin, A.I. The origin of life and the origin of enzymes. *Adv. Enzymol. Relat. Areas Mol. Biol.* 1965, **27**, 347–380. [CrossRef] [PubMed]

2. Zwicker, D.; Seyboldt, R.; Weber, C.A.; Hyman, A.A.; Jülicher, F. Growth and division of active droplets provides a model for protocells. *Nat. Phys.* 2017, **13**, 408–413. [CrossRef]

3. Gilbert, W. Origin of life: The RNA world. *Nature* 1986, **319**, 618. [CrossRef]

4. Higgs, P.G.; Lehman, N. The RNA World: Molecular cooperation at the origins of life. *Nat. Rev. Genet.* 2015, **16**, 7–17. [CrossRef] [PubMed]

5. Inoue, T.; Sullivan, F.X.; Cech, T.R. Intermolecular exon ligation of the rRNA precursor of Tetrahymena: Oligonucleotides can function as 5′ exons. *Cell* 1985, **43**, 431–437. [CrossRef]

6. Dai, X.; Zhang, S.; Zaleta-Rivera, K. RNA: Interactions drive functionalities. *Mol. Biol. Rep.* 2020, **47**, 1413–1434. [CrossRef]

7. Richard Boland, C. Non-coding RNA: It’s not junk. *Dig. Dis. Sci.* 2017, **62**, 1107–1109. [CrossRef]

8. Palazzo, A.F.; Lee, E.S. Non-coding RNA: What is functional and what is junk? *Front. Genet.* 2015, **6**, 2. [CrossRef]

9. Cech, T.R.; Steitz, J.A. The noncoding RNA revolution-trashing old rules to forge new ones. *Cell* 2014, **157**, 77–94. [CrossRef]

10. Demoulin, C.F.; Lara, Y.J.; Cornet, L.; François, C.; Baurain, D.; Wilmotte, A.; Javaux, E.J. Cyanobacteria evolution: Insight from the fossil record. *Free Radic. Biol. Med.* 2019, **140**, 206–223. [CrossRef] [PubMed]

11. Hodgskiss, M.S.W.; Crockford, P.W.; Peng, Y.; Wing, B.A.; Horner, T.J. A productivity collapse to end Earth’s Great Oxidation. *Proc. Natl. Acad. Sci. USA* 2019, **116**, 17207–17212. [CrossRef]

12. Finkel, T.; Holbrook, N.J. Oxidants, oxidative stress and the biology of ageing. *Nature* 2000, **408**, 239–247. [CrossRef] [PubMed]

13. Kinoshita, C.; Aoyama, K.; Nakaki, T. microRNA as a new agent for regulating neuronal glutathione synthesis and metabolism. *AIMS Mol. Sci.* 2015, **1**, 124–143. [CrossRef]

14. Poprac, P.; Jomova, K.; Simunkova, M.; Kollar, V.; Rhodes, C.J.; Valko, M. Targeting free radicals in oxidative stress-related human diseases. *Trends Pharmacol. Sci.* 2017. [CrossRef] [PubMed]

15. Gonzalez-Freire, M.; de Cabo, R.; Bernier, M.; Sollott, S.J.; Fabbrì, E.; Navas, P.; Ferrucci, L. Reconsidering the role of mitochondria in ageing. *J. Gerontol. A Biol. Sci. Med. Sci.* 2015, **70**, 1334–1342. [CrossRef] [PubMed]

16. Ademowo, O.S.; Dias, H.K.I.; Burton, D.G.A.; Griffiths, H.R. Lipid (per)oxidation in mitochondria: An emerging target in the ageing process? *Biogerontology* 2017. [CrossRef]

17. Aoyama, K.; Watabe, M.; Nakaki, T. Regulation of neuronal glutathione synthesis. *J. Pharm. Sci.* 2008, **98**, 227–238. [CrossRef]

18. Temiz, M.A.; Temur, A.; Elik, S. Antioxidant role and hepatoprotective effects of carob (*Ceratonia siliqua L.*) seeds against ethanol-induced oxidative stress in rats. *J. Food Nutr. Res.* 2015, **3**, 57–61. [CrossRef]

19. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* 2006, **443**, 787–795. [CrossRef]

20. Wu, Y.Y.; Kuo, H.C. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. *J. Biomed. Sci.* 2020, **27**, 49. [CrossRef] [PubMed]

21. Pizzino, G.; Irrera, N.; Cucinotta, M.; Palillo, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative stress: Harms and benefits for human health. *Oxid. Med. Cell. Longev.* 2017, **2017**, 8416763. [CrossRef]

22. Ghezzi, P.; Jaquet, V.; Marcucci, F.; Schmidt, H. The oxidative stress theory of disease: Levels of evidence and epistemological aspects. *Br. J. Pharm.* 2017, **174**, 1784–1796. [CrossRef]

23. Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. *Curr. Biol.* 2014, **24**, R453–R462. [CrossRef] [PubMed]

24. Sies, H.; Jones, D.P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. *Nat. Rev. Mol. Cell Biol.* 2020, **21**, 363–383. [CrossRef] [PubMed]

25. Ray, P.D.; Huang, B.W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell. Signal.* 2012, **24**, 981–990. [CrossRef] [PubMed]
26. Liochev, S.I. Reactive oxygen species and the free radical theory of aging. Free Radic. Biol. Med. 2013, 60, 1–4. [CrossRef]
27. Aoyama, K.; Nakaki, T. Impaired glutathione synthesis in neurodegeneration. Int. J. Mol. Sci. 2013, 14, 21021–21044. [CrossRef]
28. Janáky, R.; Varga, V.; Hermann, A.; Sararsaarti, P.; Oja, S.S. Mechanisms of L-cysteine neurotoxicity. Neurochem. Res. 2000, 25, 1397–1405. [CrossRef] [PubMed]
29. Paul, B.D.; Sbodio, J.I.; Snyder, S.H. Cysteine metabolism in neuronal redox homeostasis. Trends Pharm. Sci. 2018, 39, 513–524. [CrossRef] [PubMed]
30. Hughes, C.E.; Coody, T.K.; Jeong, M.Y.; Berg, J.A.; Winge, D.R.; Hughes, A.L. Cysteine toxicity drives age-related mitochondrial decline by altering iron homeostasis. Cell 2020, 180, 296–310.e18. [CrossRef]
31. Dringen, R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62, 649–671. [CrossRef]
32. Lu, S.C. Glutathione synthesis. Mol. Asp. Med. 2009, 30, 42–59. [CrossRef]
33. Backos, D.S.; Fritz, K.S.; Roeade, J.R.; Petersen, D.R.; Franklin, C.C. Posttranslational modification and regulation of glutamate-cysteine ligase by the α,β-unsaturated aldehyde 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 2011, 50, 14–26. [CrossRef]
34. Liu, Y.; Hyde, A.S.; Simpson, M.A.; Barycki, J.J. Emerging regulatory paradigms in glutathione metabolism. Adv. Cancer Res. 2014, 122, 69–101. [CrossRef] [PubMed]
35. Steullet, P.; Cabungcal, J.H.; Kulak, A.; Kraftsik, R.; Chen, Y.; Dalton, T.P.; Cuenod, M.; Do, K.Q. Redox dysregulation affects the ventral but not dorsal hippocampus: Impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J. Neurosci. 2010, 30, 2547–2558. [CrossRef] [PubMed]
36. Feng, W.; Rosca, M.; Fan, Y.; Hu, Y.; Feng, P.; Lee, H.G.; Mornier, V.M.; Fan, X. Gclc deficiency in mouse CNS causes mitochondrial damage and neurodegeneration. Mol. Genet. 2017, 26, 1376–1390. [CrossRef]
37. Lu, S.C. Regulation of glutathione synthesis. Mol. Asp. Med. 2009, 30, 42–59. [CrossRef]
38. Winkler, A.; Njålsson, R.; Carlsson, K.; Elgadi, A.; Rozell, B.; Abraham, L.; Ercal, N.; Shi, Z.Z.; Lieberman, M.W.; Larsson, A.; et al. Glutathione is essential for early embryogenesis—Analysis of a glutathione synthetase knockout mouse. Biochem. Biophys. Res. Commun. 2011, 412, 121–126. [CrossRef]
39. Ristoff, E.; Larsson, A. Inborn errors in the metabolism of glutathione. Orphanet J. Rare Dis. 2007, 2, 16. [CrossRef] [PubMed]
40. Guevara-Flores, A.; Martinez-González, J.J.; Rendón, J.L.; Del Arenal, I.P. The architecture of thiol antioxidant systems among invertebrate parasites. Molecules 2017, 22, 259. [CrossRef] [PubMed]
41. Couto, N.; Wood, J.; Barber, J. The role of glutathione reductase and related enzymes on cellular redox homeostasis network. Free Radic. Biol. Med. 2016, 95, 27–42. [CrossRef] [PubMed]
42. Forman, H.J.; Zhang, H.; Rinna, A. Glutathione: Overview of its protective roles, measurement, and biosynthesis. Mol. Asp. Med. 2009, 30, 1–12. [CrossRef] [PubMed]
43. Kalinina, E.V.; Chernov, N.N.; Novikovchina, M.D. Role of glutathione, glutathione transferase, and glutaredoxin in regulation of redox-dependent processes. Biochemistry 2014, 79, 1562–1583. [CrossRef] [PubMed]
44. Ballatori, N.; Krance, S.M.; Marchan, R.; Hammond, C.L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol. Asp. Med. 2009, 30, 13–28. [CrossRef] [PubMed]
45. Dringen, R.; Brandmann, M.; Hohnholt, M.C.; Blumrich, E.M. Glutathione-dependent detoxification processes in astrocytes. Neurochem. Res. 2015, 40, 2570–2582. [CrossRef]
46. Bachhawat, A.K.; Yadav, S. The glutathione cycle: Glutathione metabolism beyond the γ-glutamyl cycle. IUBMB Life 2018, 70, 585–592. [CrossRef]
47. Greenwald, R.A. Superoxide dismutase and catalase as therapeutic agents for human diseases. A critical review. Free Radic. Biol. Med. 1990, 8, 201–209. [CrossRef]
48. Wang, Y.; Branicky, R.; Noë, A.; Hekimi, S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J. Cell Biol. 2018, 217, 1915–1928. [CrossRef]
49. Goyal, M.M.; Basak, A. Human catalase: Looking for complete identity. Protein Cell 2010, 1, 888–897. [CrossRef]
50. Brigelius-Flohe, R.; Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta 2013, 1830, 3289–3303. [CrossRef]
51. Zelko, I.N.; Mariani, T.J.; Fozl, R.J. Superoxide dismutase multigene family: A comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med. 2002, 33, 337–349. [CrossRef]
52. Miao, L.; St Clair, D.K. Regulation of superoxide dismutase genes: Implications in disease. Free Radic. Biol. Med. 2009, 47, 344–356. [CrossRef] [PubMed]
53. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O’Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59–62. [CrossRef]
54. McAlary, L.; Aquilina, J.A.; Yerbury, J.J. Susceptibility of mutant SOD1 to form a destabilized monomer predicts cellular toxicity and attractiveness but not in vitro aggregation propensity. Front. Neurosci. 2016, 10, 499. [CrossRef]
55. Góth, L.; Rass, P.; Páy, A. Catalase enzyme mutations and their association with diseases. Mol. Diagn. 2004, 8, 141–149. [CrossRef]
56. Ho, Y.S.; Xiong, Y.; Ma, W.; Spector, A.; Ho, D.S. Mice lacking catalase develop normally but show differential sensitivity to oxidative tissue injury. J. Biol. Chem. 2004, 279, 32804–32812. [CrossRef] [PubMed]
57. Hirono, A.; Sasaya-Hamada, F.; Kanno, H.; Fujii, H.; Yoshida, T.; Miwa, S. A novel human catalase mutation (358 T->del) causing Japanese-type acatalasemia. Blood Cells Mol. Dis. 1995, 21, 232–234. [CrossRef] [PubMed]
58. Takahara, S. Progressive oral gangrene probably due to lack of catalase in the blood (acatalasaemia): Report of nine cases. *Lancet* 1952, 2, 1101–1104. [CrossRef]

59. Margis, R.; Dunand, C.; Teixeira, F.K.; Margis-Pinheiro, M. Glutathione peroxidase family—An evolutionary overview. *FEBS J.* 2008, 275, 3959–3970. [CrossRef]

60. Girott, A.W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. *J. Lipid Res.* 1998, 39, 1529–1542. [CrossRef]

61. Lei, X.G. Glutathione peroxidase-1 gene knockout on body antioxidant defense in mice. *BioFactors* 2001, 14, 93–99. [CrossRef]

62. De Haan, J.B.; Crack, P.J.; Frisvold, G.; Iannello, R.C.; Hertzog, P.J.; Kola, I. An imbalance in antioxidant defense affects cellular function: The pathophysiological consequences of a reduction in antioxidant defense in the glutathione peroxidase-1 (Gpx1) knockout mouse. *Redox Rep.* 2003, 8, 69–79. [CrossRef] [PubMed]

63. Crack, P.J.; Cimdins, K.; Ali, U.; Hertzog, P.J.; Iannello, R.C. Lack of glutathione peroxidase-1 exacerbates Abeta-mediated neurotoxicity in cortical neurons. *J. Neurotransm.* 2006, 113, 645–657. [CrossRef] [PubMed]

64. Ran, Q.; Van Remmen, H.; Gu, M.; Qi, W.; Roberts, L.J., 2nd; Prolla, T.; Richardson, A. Embryonic fibroblasts from Gpx4+/- mice: A novel model for studying the role of membrane peroxidation in biological processes. *Free Radic. Biol. Med.* 2003, 35, 1101–1109. [CrossRef]

65. Ran, Q.; Liang, H.; Ikeno, Y.; Qi, W.; Prolla, T.A.; Roberts, L.J., 2nd; Wolf, N.; Van Remmen, H.; Richardson, A. Reduction in glutathione peroxidase 4 increases life span through increased sensitivity to apoptosis. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2007, 62, 932–942. [CrossRef] [PubMed]

66. Chen, L.; Na, R.; Gu, M.; Richardson, A.; Ran, Q. Lipid peroxidation up-regulates BACE1 expression in vivo: A possible early event of amyloidogenesis in Alzheimer’s disease. *J. Neurochem.* 2008, 107, 197–207. [CrossRef] [PubMed]

67. Lillig, C.H.; Berndt, C.; Holmgren, A. Glutaredoxin systems. *Biochim. Biophys. Acta* 2008, 1780, 1304–1317. [CrossRef]

68. Lu, J.; Holmgren, A. The thioredoxin antioxidant system. *Antioxid. Redox Signal.* 2014, 66, 75–87. [CrossRef] [PubMed]

69. Hanschmann, E.M.; Godoy, J.R.; Berndt, C.; Hudemann, C.; Lillig, C.H. Thioredoxins, glutaredoxins, and peroxiredoxins—Molecular mechanisms and health significance: From cofactors to antioxidants to redox signaling. *Antioxid. Redox Signal.* 2013, 19, 1539–1605. [CrossRef]

70. Rhee, S.G. Overview on Peroxiredoxin. *Mol. Cells* 2016, 39, 1–5. [CrossRef] [PubMed]

71. Suzuki, T.; Yamamoto, M. Molecular basis of the Keap1-Nrf2 system. *Free Radic. Biol. Med.* 2015, 88, 93–100. [CrossRef] [PubMed]

72. Yamamoto, M.; Kensler, T.W.; Motohashi, H. The KEAP1-NRF2 system: A thiol-based sensor-effector apparatus for maintaining cellular redox homeostasis. *Physiol. Rev.* 2018, 98, 1169–1203. [CrossRef] [PubMed]

73. Fledderus, J.O.; Boon, R.A.; Volger, O.L.; Huttula, H.; Ylä-Herttuala, S.; Pannekoek, H.; Levonen, A.L.; Horrevoets, A.J. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* 2008, 28, 1339–1346. [CrossRef]

74. Abdalkader, M.; Lampinen, R.; Kanninen, K.M.; Malm, T.M.; Liddell, J.R. Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. *Front. Neurosci.* 2018, 12, 466. [CrossRef]

75. Xie, Y.Z.; Zhang, X.J.; Zhang, C.; Yang, Y.; He, J.N.; Chen, Y.X. Protective effects of leonurine against ischemic stroke in mice by activating nuclear factor erythroid 2-related factor 2 pathway. *CNS Neurosci. Ther.* 2019, 25, 1006–1017. [CrossRef]

76. Shi, A.Y.; Li, P.; Murphy, T.H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. *J. Neurosci.* 2005, 25, 10321–10335. [CrossRef] [PubMed]

77. Aoyama, K.; Suh, S.W.; Hambry, A.M.; Liu, J.; Chan, W.Y.; Chen, Y.; Swanson, R.A. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. *Nat. Neurosci.* 2006, 9, 119–126. [CrossRef]

78. Escartin, C.; Won, S.J.; Malgorn, C.; Auregan, G.; Berman, A.E.; Chen, P.C.; Déglon, N.; Johnson, J.A.; Suh, S.W.; Swanson, R.A. Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression. *J. Neurosci.* 2011, 31, 7392–7401. [CrossRef]

79. Kanai, Y.; Hediger, M.A. The glutamate and neutral amino acid transporter family: Physiological and pharmacological implications. *Eur. J. Pharmacol.* 2003, 479, 237–247. [CrossRef] [PubMed]

80. Zerangue, N.; Kavenaugh, M.P. Flux coupling in a neuronal glutamate transporter. *Nature* 1996, 383, 634–637. [CrossRef] [PubMed]

81. Zerangue, N.; Kavenaugh, M.P. Interaction of L-cysteine with a human excitatory amino acid transporter. *J. Physiol.* 1996, 493, 419–423. [CrossRef] [PubMed]

82. Watts, S.D.; Torres-Salazar, D.; Divito, C.B.; Amara, S.G. Cysteine transport through excitatory amino acid transporter 3 (EAAT3). *PloS ONE* 2014, 9, e109245. [CrossRef]

83. Malik, A.R.; Willnow, T.E. Excitatory amino acid transporters in physiology and disorders of the central nervous system. *Int. J. Mol. Sci.* 2019, 20, 5671. [CrossRef] [PubMed]

84. Bannai, S. Transport of cystine and cysteine in mammalian cells. *Biochim. Biophys. Acta* 1984, 779, 289–306. [CrossRef]

85. Massie, A.; Boillee, S.; Hewett, S.; Knackstedt, L.; Leverenz, J. Main path and byways: Non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission. *J. Neurochem.* 2015, 135, 1062–1079. [CrossRef]

86. Pow, D.V. Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminooacidic acid, a selectively transported substrate. *Glia* 2001, 34, 27–38. [CrossRef]
115. Zhang, Y.; Xu, W.; Nan, S.; Chang, M.; Fan, J. MicroRNA-326 inhibits apoptosis and promotes proliferation of dopaminergic neurons in Parkinson’s disease through suppression of KLK7-mediated MAPK signaling pathway. J. Mol. Neurosci. 2019, 69, 197–214. [CrossRef]

116. Qu, X.; Wang, N.; Cheng, W.; Xue, Y.; Chen, W.; Qi, M. MicroRNA-146a protects against intracerebral hemorrhage by inhibiting inflammation and oxidative stress. Exp. Ther. Med. 2019, 18, 3920–3928. [CrossRef] [PubMed]

117. Chen, F.Z.; Zhao, Y.; Chen, H.Z. MicroRNA-98 reduces amyloid β-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer’s disease mice. Int. J. Mol. Med. 2019, 43, 91–102. [CrossRef] [PubMed]

118. Wang, B.; Li, Y.; You, C. miR-129-3p targeting of MCU protects against glucose fluctuation-mediated neuronal damage via a mitochondria-dependent intrinsic apoptotic pathway. Diab. Metab. Synd. Obesity 2021, 14, 153–163. [CrossRef]

119. Wu, D.M.; Wang, S.; Wen, X.; Han, X.R.; Wang, Y.J.; Shen, M.; Fan, S.H.; Zhuang, J.; Zhang, Z.F.; Shan, Q.; et al. Inhibition of microRNA-200a upregulates the expression of striatal dopamine receptor D2 to repress apoptosis of striatum via the cAMP/PKA signaling pathway in rats with Parkinson’s disease. Cell. Physiol. Biochem. 2018, 51, 1600–1615. [CrossRef]

120. Shen, W.; Lu, Y.; Hu, J.; Le, H.; Yu, W.; Xu, W.; Yu, W.; Zheng, J. Mechanism of miR-320 in regulating biological characteristics of ischemic cerebral neuron by mediating Nox2/ROS pathway. J. Mol. Neurosci. 2020, 70, 449–457. [CrossRef] [PubMed]

121. Kinoshita, C.; Aoyama, K.; Matsumura, N.; Kikuchi-Utsumi, K.; Watabe, M.; Nakaki, T. Rhythmic oscillations of the microRNA-117. [CrossRef] [PubMed]

122. Kinoshita, C.; Kikuchi-Utsumi, K.; Aoyama, K.; Suzuki, R.; Okamoto, Y.; Omata, D.; Maruyama, K.; Nakaki, T. Inhibition of miR-96-5p in the mouse brain increases glutathione levels by altering NOVA1 expression. Commun. Biol. 2021, 4, 182. [CrossRef] [PubMed]

123. Park, H.A.; Kubicki, N.; Gnyawali, S.; Chan, Y.C.; Roy, S.; Khanna, S.; Sen, C.K. Natural vitamin E α-tocotrienol protects against ischemic stroke by induction of multidrug resistance-associated protein 1. Stroke 2011, 42, 2308–2314. [CrossRef] [PubMed]

124. Zhou, S.; Zhang, D.; Guo, J.; Chen, Z.; Chen, Y.; Zhang, J. Deficiency of NEAT1 prevented MPP(+)-induced inflammatory response, oxidative stress and apoptosis in dopaminergic SK-N-SH neuroblastoma cells via miR-1277-5p/ARHGAP26 axis. Brain Res. 2021, 1750, 147156. [CrossRef] [PubMed]

125. Quinn, J.J.; Chang, H.Y. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 2016, 17, 47–62. [CrossRef] [PubMed]

126. Zhou, S.; Zhang, D.; Guo, J.; Chen, Z.; Chen, Y.; Zhang, J. Deficiency of NEAT1 prevented MPP(+)-induced inflammatory response, oxidative stress and apoptosis in dopaminergic SK-N-SH neuroblastoma cells via miR-1277-5p/ARHGAP26 axis. Brain Res. 2021, 1750, 147156. [CrossRef] [PubMed]

127. Wang, C.; Wan, H.; Wang, Q.; Sun, H.; Sun, Y.; Wang, K.; Zhang, C. Safflor Yellow B attenuates ischemic brain injury via downregulation of long noncoding AK046177 and inhibition of MICORRNA-134 expression in rats. Oxid. Med. Cell. Longev. 2020, 4586839. [CrossRef]

128. Nordin, M.; Bergman, D.; Halje, M.; Engström, W.; Ward, A. Epigenetic regulation of the Igf2/H19 gene cluster. Cell Proliferat. 2014, 47, 189–199. [CrossRef]

129. Zeng, J.; Zhu, L.; Liu, J.; Zhu, T.; Xie, Z.; Sun, X.; Zhang, H. Metformin Protects against Oxidative Stress Injury Induced by Ischemia/Reperfusion via Regulation of the IncRNA-H19/miR-148a-3p/ROCK2 Axis. Oxid. Med. Cell. Longev. 2019, 2019, 8768327. [CrossRef]

130. Li, Y.; Fang, J.; Zhou, Z.; Zhou, Q.; Sun, S.; Jin, Z.; Xi, Z.; Wei, J. Downregulation of IncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson’s disease by upregulating microRNA-34b-5p and downregulating BACE1. Cell Cycle 2020, 19, 1158–1171. [CrossRef]

131. Wang, Q.; Ge, X.; Zhang, J.; Chen, L. Effect of IncRNA WT1-AS regulating WT1 on oxidative stress injury and apoptosis of neurons in Alzheimer’s disease via inhibition of the miR-375/SIX4 axis. Aging 2020, 12, 23974–23995. [CrossRef]

132. Zhang, L.; Fang, Y.; Cheng, X.; Lian, Y.J.; Yu, H.L. Silencing of long noncoding RNA SOX21-AS1 relieves neuronal oxidative stress injury in mice with Alzheimer’s disease by upregulating FZD3/5 via the Wnt signaling pathway. Mol. Neurobiol. 2019, 56, 3522–3537. [CrossRef] [PubMed]

133. Hansen, T.B.; Jensen, T.I.; Clausen, B.H.; Bramsen, J.B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495, 384–388. [CrossRef] [PubMed]

134. Hansen, T.B.; Kjems, J.; Damgaard, C.K. Circular RNA and miR-7 in cancer. Cancer Res. 2013, 73, 5609–5612. [CrossRef] [PubMed]

135. Li, Y.; Cheng, T.; Wan, C.; Cang, Y. circRNA_0084043 contributes to the progression of diabetic retinopathy via splicing miR-140-3p and inducing TGFA gene expression in retinal pigment epithelial cells. Gene 2020, 747, 144653. [CrossRef] [PubMed]

136. Cui, G.; Wang, L.; Huang, W. Circular RNA HIPK3 regulates human lens epithelial cell dysfunction by targeting the miR-221-3p/PI3K/AKT pathway in age-related cataract. Exp. Eye Res. 2020, 198, 108128. [CrossRef]

137. Bai, M.; Pan, C.L.; Jiang, G.X.; Zhang, Y.M.; Zhang, Z. CircHIPK3 aggravates myocardial ischemia-reperfusion injury by binding to miRNA-124-3p. Eur. Rev. Med. Pharm. Sci. 2019, 23, 10107–10114. [CrossRef]
139. Cai, Y.; Xu, L.; Xu, C.; Wang, Y.; Fan, C. Hsa_circ_0001445 inhibits ox-LDL-induced HUVECs inflammation, oxidative stress and apoptosis by regulating miRNA-640. *Perfusion* 2020. [CrossRef]

140. Xu, Q.; Zhou, L.; Yang, G.; Meng, F.; Wan, Y.; Wang, L.; Zhang, L. CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis. *Cell Biol. Int.* 2020, 44, 2344–2356. [CrossRef]

141. Wu, P.; Li, C.; Ye, D.M.; Yu, K.; Li, Y.; Tang, H.; Xu, G.; Yi, S.; Zhang, Z. Circular RNA circEPSTI1 accelerates cervical cancer progression via miR-375/409-3P/515-5p-SLC7A11 axis. *Aging* 2021, 13. [CrossRef] [PubMed]